Results 101 to 110 of about 4,565 (192)

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

Cancer Treatment and Research Communications
Background: In untreated ALK-positive non-small cell lung cancer no randomized controlled trials (RCTs) are available directly comparing next-generation ALK-inhibitors.
Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria   +9 more
doaj   +1 more source

Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer

Frontiers in Oncology
BackgroundOver the past decade, progress in the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC) has led to the identification of many targeted mutations. This has enhanced PFS and OS in both advanced and early-stage NSCLC.
Waleed Kian, Waleed Kian, Waleed Kian, Belal Krayim, Betsy Giles, Nasim A. Elkiaan, Amjad Idris, Daniel Fink, Nir Peled, Laila C. Roisman   +9 more
doaj   +1 more source

ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia

Lung Cancer: Targets and Therapy, 2023
Alexandria TM Lee,1 Saihong Ignatius Ou1,2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, USACorrespondence: Saihong Ignatius Ou, University of ...
Lee AT, Ou SI
doaj  

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion [PDF]

, 2023
Bironzo, Paolo
core   +1 more source

High efficacy of brigatinib for brain metastases in ALK fusion gene‐positive non‐small cell lung cancer: A case series

Thoracic Cancer
Anaplastic lymphoma kinase (ALK) fusion gene‐positive lung cancer often shows brain metastasis at initial diagnosis or during the course of treatment.
Kei Morikawa, Yu Numata, Yusuke Shinozaki, Shotaro Kaneko, Aya Matsushima, Makoto Nishida, Hirotaka Kida, Hiroshi Handa, Hiroki Nishine, Masamichi Mineshita   +9 more
doaj   +1 more source

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Drug Design, Development and Therapy, 2019
Robert Ali,1 Junaid Arshad,1 Sofia Palacio,1 Raja Mudad2 1Department of Medicine, Division of Oncology, Jackson Memorial Hospital, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Centre, Miami, FL 33131, USA; 2Department ...
Ali R, Arshad J, Palacio S, Mudad R
doaj  

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]

, 2017
Jalal, Shadia I., Mamdani, Hirva
core   +1 more source

Issue Information

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 7, July 2025.
wiley   +1 more source

Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report

Frontiers in Oncology
The management of non-small cell lung cancer (NSCLC), specifically targeting the anaplastic lymphoma kinase (ALK) with tyrosine kinase inhibitors (TKIs), is challenged by the emergence of therapeutic resistance.
Dan Li, Yue Zhu, Jincheng Song, Dafu Yang, Saiqiong Cui, Xin Liu, Le Wang, Jiangyan Zhang, Evenki Pan, Zhaoxia Dai   +9 more
doaj   +1 more source

Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis

BMC Cancer
Objectives To compare the efficacy, safety and effects on quality of life of different ALK-inhibitors for global and Asian patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).
Mingye Zhao, Taihang Shao, Hanqiao Shao, Caicun Zhou, Wenxi Tang   +4 more
doaj   +1 more source